Optimized preparation of poly D,L (lactic-glycolic) microspheres and nanoparticles for oral administration

International Journal of Pharmaceutics

Volumn 141, Issue 1-2, 1996, Pages 81-91

  Chacon M ^a   Berges, L ^a   Molpeceres, J ^a   Aberturas, M R ^a   Guzman, M ^a  

^a UNIVERSITY OF ALCALÁ   (Spain)

Author keywords

Cyclosporin A; Experimental Designs; Microspheres; Nanoparticles; Poly D,L (lactide glycolide)

Indexed keywords

CYCLOSPORIN A; MICROSPHERE; NANOPARTICLE; POLYGLACTIN;

ARTICLE; ENCAPSULATION; EVAPORATION; PARTICLE SIZE; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; TECHNIQUE;

EID: 0030572633     PISSN: 03785173     EISSN: None     Source Type: Journal    
DOI: 10.1016/0378-5173(96)04618-2     Document Type: Article

References (44)

1. Akbarieh, M., Adam, A., Legris, F. and Tawashi, R., Reduced kallikrein excretion by liposome-encapsulated cyclosporin in the rat. J. Pharm. Pharmacol., 45 (1993) 146-148.
2. Al-Angary, A.A., Bayomi, M.A., Khidr, S.H., Al-Meshal, M.A. and Al-Dardiri, M., Characterization, stability and in vivo targeting of liposomal formulations containing cyclosporin. Int. J. Pharm., 114 (1995) 221-225.
3. Alonso, M.J., Sánchez, A., Torres, D., Seijo, B. and Vila Jato, J.L., Joint effects of monomer and stabilizer concentrations on physico-chemical characteristics of poly(buty1 2-cyanoacrylate) nanoparticles. J. Microencapsulation, 7 (1990) 517-526.
4. Berges, L., Chacón, M., Molpeceres, J., Guzmán, M., Garcia, F., Aberturas, M.R. and Salsa T., Encapsulation efficiency of cyclosporin A in poly D.L-lactide-glycolide colloidal drug carriers. 1st Spanish Portuguese Conf. on Controlled Drug Delivery, 1995, Santiago de Compostela, Spain, pp. 52.
5. Bodmeier, R. and McGinity, J.W., The preparation and evaluation of drug-contained poly(D.L-lactide) microspheres formed by the solvent evaporation method. Pharm. Res., 4 (1987) 465-468.
6. Bonduelle, S., Pimienta, C., Benoit, J.P. and Lenaerts, V., Body distribution in mice of intravenously injected radiolabelled cyclosporin associated with polyisohexylcyanoacrylate nanocapsules or nanospheres. Eur. J. Pharm. Biopharm., 41 (1995) 27-30.
7. Chen, H. and Bodmeier, R., Cross-sectional structures of and drug release from polymeric microspheres prepared by solvent evaporation methods. Pharm. Res., 7 (1991) s148.
8. Eldridge, J.H., Hammond, C.J., Meulbroek, J.A., Staas, J.K., Gilley, R.M. and Tice, T.R., Controlled vaccine release in the gut-associated lymphoid tissues. I: Orally administered biodegradable microspheres target the Peyer's patches. J. Control. Release, 11 (1990) 205-214.
9. Fessi, H., Puisieux, F., Devissaguet, J.P., Ammoury, N. and Benita, S., Nanocapsule formation by interfacial polymer deposition following solvent displacement Int. J. Pharm. 55 (1989) R1-R4.
10. González, A.G., Optimization of pharmaceutical formulations based on response-surface experimental designs. Int. J. Pharm., 97 (1993) 149-159.
11. Gruber, S.A., Venkataram, S., Canafax, D.M., Cipolle, R.J., Bowers, L., Elsberry, D., McGuiggan, M., Hynes, P.E., Ritz, J.A., Gould, F.H., Matas, A., Hrushesky, J,M, and Rahman, Y., Liposomal formulation eliminates acute toxicity and pump incompatibility of parenteral cyclosporine. Pharm. Res., 6 (1989) 601-607.
12. Guzmán, M., Molpeceres, J., García, F., Aberturas, M.R. and Rodríguez, M., The formation and characterization of CyA-loaded nanoparticles. J. Pharm. Sci. 82 (1993) 498-502.
13. Harmia, T., Speiser, P. and Kreuter, J., Nanoparticles as drug carriers in ophthalmology. Pharm. Acta Helv., 62 (1987) 322-331.
14. Hintze, J.L., Number Cruncher Statistical System. 5.03 9/92, Utah, U.S., 1992.
15. Illum, L., Khan, M.A., Mark, E. and Davis, S.S. Evaluation of carrier capacity and release characteristics for poly(-buty1-2-cyanoacrylate) nanoparticles. Int. J. Pharm., 30 (1986) 17-28.
16. Jani, P., Halbert, G.W., Langridge, J. and Florence, A.T., Nanoparticle uptake by the rat gastrointestinal mucosa: quantification and particle size dependency. J. Pharm. Pharmacol., 42 (1990) 821-826.
17. Jani, P.U., McCarthy, E. and Florence, A., Titanium dioxide (rutile) particle uptake from the rat GI tract and translocation to sistemic organs after oral administration. Int. J. Pharm., 105 (1994) 157-168.
18. Jeffery, H., Davis, S.S. and O'Hagan, D.T., The preparation and characterization of poly(lactide-co-glycolide) microparticles. I: Oil-in-water emulsion solvent evaporation. Int. J. Pharm., 77 (1991) 169-175.
19. Jeyanthi, R., Thanoo, B.C., Mehta, R.C. and DeLuca, P.P., Effect of solvent removal technique on the matrix characteristics of peptide-loaded PLGA microspheres. Pharm. Res., 10 (1993) s277.
20. Julienne, M.C., Alonso, M.J., Gómez Amoza, J.L. and Benoit, J.P., Preparation of poly(D,L-lactide/glycolide) nanoparticles of controlled particle size distribution: application of experimental designs. Drug Dev. Ind. Pharm., 18 (1992) 1063-1077.
21. Keenan, R.J., Duncan, A.J., Yousem, S.A., Zenati, M., Schaper, M., Dowling, R.D., Alarie, Y., Burckart, G.J. and Griffith, B.P., Improved immunosuppression with aerosolized cyclosporin in experimental pulmonary transplantation. Transpl. Proc., 53 (1992) 20-25.
22. Kreuter, J., Peroral administration of nanoparticles. Adv. Drug Deliv. Rev., 7 (1991) 71-86.
23. Losa, C., Marchal-Heussler, L., Orallo, F., Vila-Jato, J.L. and Alonso, M.J., Design of new formulations for topical ocular administration: polymeric nanocapsules containing metipranolol. Pharm. Res., 10 (1993) 80-87.
24. Marchal-Heussler, L., Sirbat, D., Huffman, M. and Maincent P., Poly(Σ-caprolactone) nanocapsules in carteolol ophthalmic delivery. Pharm. Res., 10 (1993) 386-390.
25. McLeod, A.D., Lam, F.C., Gupta, P.K. and Hung, C.T., Optimized synthesis of polyglutaraldehyde nanoparticles using central composite design. J. Pharm. Sci., 77 (1988) 704-710.
26. Molpeceres, J., Nuevos sistemas de administratión de fármacos: Nanopartículas de poli-∈-caprolactona cargadas con ciclosporina A. Ph.D. Thesis, University of Alcalá de Henares, Spain (1994).
27. Molpeceres, J., Guzmán, M., Aberturas, M.R., Chacón, M. and Berges, L., Application of central composite designs to the preparation of polycaprolactone nanoparticles by solvent displacement. J. Pharm. Sci., 85 (1996) 206-213.
28. Mueller, E.A., Kovarik, J.M., Van Bree, J.B., Tetzloff, W., Grevel, J. and Kutz, K., Improved dose linearity of cyclosporine pharmacokinetics from a microemulsion formulation. Pharm. Res., 11 (1994) 301-304.
29. Oh, C., Saville, B.A., Cheng, Y. and Rootman, D.S., A compartmental model for the ocular pharmacokinetics of cyclosporine in rabbits. Pharm. Res., 12 (1995) 433-437.
30. Ptachcinski, R.J., Venkataramanan, R. and Burckart, G.J., Clinical pharmacokinetics of cyclosporin. Clin. Pharmacokinet., 11 (1986) 107-132.
31. Rolland, A., Bourel, D., Genetet, B. and Le Verge, R., Monoclonal antibodies covalently coupled to polymethacrylic nanoparticles: in vitro specific targeting to human T lymphocytes. Int. J. Pharm., 39 (1987) 173-180.
32. Rolland, A., Wagner, N., Chatelus, A., Shroot, B. and Schaefer H., Site-specific drug delivery to pilosebaceous structures using polymeric microspheres. Pharm. Res., 10 (1993) 1738-1744.
33. Sánchez, A. and Alonso, M.J., Poly(D.L-lactide-co-glycolide) micro and nanospheres as a way to prolong blood/plasma levels of subcutaneously injected cyclosporin A. Eur. J. Pharm. Biopharm., 41 (1995) 31-37.
34. Sánchez, A., Vila-Jato, J.L. and Alonso, M.J., Development of biodegradable microspheres and nanospheres for the controlled release of cyclosporin A. Int. J. Pharm., 99 (1993) 263-273.
35. Sandborn, W.J., Strong, R.M., Forland, S.C., Chase, R.E. and Cutler, R.E. The pharmacokinetics and colonic tissue concentrations of cyclosporine after IV, oral, and enema administration. J. Clin. Pharmacol., 31 (1991) 76-80.
36. Sansdrap, P. and Moës, A.J., Influence of manufacturing parameters on the size characteristics and the release profiles of nifedipine from poly(DL-lactide.co-glycolide) microspheres. Int. J. Pharm., 98 (1993) 157-164.
37. Stuhne-Sekalec, L. and Stanacev, N.Z., Liposomes as carriers of cyclosporin A. J. Microencapsulation, 18 (1991) 441-446.
38. Takada, K., Oh-Hashi, M., Furuya, Y., Yoshikawa, H. and Muranishi, S., Enteric solid dispersion of cyclosporin A (CyA) having potential to improve availability of CyA in rabbit. Chem. Pharm. Bull., 37 (1989) 2542-2544.
39. Vadiei, K., Perez-Soler, R., Lopez-Berenstein, G. and Luke, D.R., Pharmacokinetic and pharmacodynamic evaluation of liposomal cyclosporin. Int. J. Pharm., 57 (1989) 125-131.
40. Vert, M., Mauduit, J. and Suming, L., Biodegradation of PLA/GA polymers: increasing complexity. Biomaterials, 15 (1994) 1209-1213.
41. Wehrle, P., Magenheim, B. and Benita, S., The influence of process parameters on the PLA nanoparticles size distribution, evaluated by means of factorial design. Eur. J. Pharm. Biopharm., 41 (1995) 19-26.
42. Yanagawa, A., Iwayama, T., Saotome, T., Shoji, Y., Takano, K., Oka, H., Nakagawa, T. and Mizushima, Y., Selective transfer of cyclosporin to thoracic lymphatic systems by the application of lipid microspheres. J. Microencapsulation, 6 (1989) 161-164.
43. Zeng, X.M., Martin, G.P. and Marriott, C., Tetrandrine delivery to the lung: the optimisation of albumin microsphere preparation by central composite design. Int. J. Pharm., 109 (1994a) 135-145.
44. Zeng, X.M., Martin, G.P. and Marriott, C., Albumin microspheres as a means of drug delivery to the lung: analysis of the effects of process variables on particle sizes using factorial design methodology. Int. J. Pharm., 107 (1994b) 205-210.